Harnessing technologies to enable complementary solutions

A combination of technology and medicines play a key role in driving innovation so naturally, we are interested in exploring how we can use devices and technologies to improve patient’s lives.

We want to build an innovative pipeline that includes new drug candidates and ground-breaking technologies. The medical device and technology market requires a completely different knowledge base to the market for (prescription) medicines. By dedicating our resources to devices and technologies, we are taking the opportunity to diversify our research projects and pipeline. A key objective is to offer complementary disease treatment options in our focus area pain.

We are focusing on two key research areas:

  • Abuse Deterrent Formulation (ADF) technology (or INTAC®) – pioneered by ourselves to significantly increase the hurdles for the misuse of opioids and other drugs with abuse potential
  • surgical sealants and the underlying technology platform – in April 2017 we acquired Adhesys Medical and the worldwide development and commercialisation rights for an innovative pipeline of surgical sealants and the supporting technology platform
External innovation is also very important to us. We are actively looking for opportunities to collaborate with third parties on the treatment of pain conditions with devices, as well as different digital methods to treat, measure and analyse data.
External Link:
You are now leaving the Grünenthal (IE) website. You will be re-directed to an external website. Grünenthal Pharma Ltd., Ireland accepts no responsibility for the content of other websites. ... Cancel ... Ok